In today's Pharmaceutical Executive Daily, FDA approves AstraZeneca's Fasenra as a new treatment for hypereosinophilic ...

According to him, the industry must address its relationship with the capital markets, address misinformation issues, and push back against the politicization of medical research and development.

Toragen is uniquely positioned to navigate this dynamic. Its HPV E5 inhibitor addresses indications that span both sexes: HPV-positive head and neck cancer affects predominantly men, cervical cancer ...

Hypereosinophilic syndrome is defined by persistent eosinophilia with eosinophil-mediated organ/tissue damage, driving ...

The takeaway leadership message from our May issue is clear: Future progress will come from those willing to rethink the machinery — not just the medicine. If there’s a common thread running through ...

A full clinical hold suspends dosing and enrollment in the Phase III HERO study and open-label extension, superseding the earlier voluntary pause and freezing near-term registrational timelines.

The current prior authorization (PA) process is an administrative failure. Beyond the excessive time and paperwork required, ...

In the first part of her interview with Pharmaceutical Executive, Sandra Coufal, MD, CEO of Toragen, explains why the HPV E5 ...

Accelerated approval of sonrotoclax establishes a targeted BCL2 option in post–BTK inhibitor relapsed/refractory mantle cell lymphoma, a setting with limited effective salvage therapies and poor ...

In today's Pharmaceutical Executive Daily, the FDA grants accelerated approval to BeOne Medicines' Beqalzi as the first and only BCL2 inhibitor for relapsed or refractory mantle cell lymphoma, while ...

ATTAIN-Maintain found oral orforglipron preserved prior loss after injection-to-oral transition, with only 0.9 kg regain from ...

Veppanu leverages PROTAC-mediated ubiquitin–proteasome degradation to eliminate mutant estrogen receptor, aiming to bypass ESR1-driven endocrine resistance rather than merely inhibiting receptor ...